Nitric oxide alterations in cardiovascular system of rats with Parkinsonism induced by 6-OHDA and submitted to previous exercise

Jager, Lorena de; Amorim, Eric Diego Turossi; Lucchetti, Bruno Fernando Cruz; Lopes, Fernanda Novi Cortegoso; Crestani, Carlos C.; Pinge‐Filho, Phileno; Martins‐Pinge, Marli Cardoso

doi:10.1016/j.lfs.2018.05.017

Cited by 9 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies using PD animal models have raised critical aspects regarding cardiovascular complications in Parkinson-like disease pathophysiology [ 30 , 32 , 83 , 84 , 85 ]. Studies on the 6-OHDA model of PD have shown the cardiovascular effects associated with dopaminergic neurodegeneration, suggesting the modulation of cardiovascular parameters by a central pathway [ 30 , 84 , 86 , 87 , 88 , 89 , 90 , 91 ]. In line with our results, Ariza [ 31 ] reported bradycardia in 6-OHDA-lesioned rats only seven days after bilateral injections in the SNc, which resulted in rapid onset of neuronal death.…”

Section: Discussionmentioning

confidence: 99%

Propolis as a Potential Disease-Modifying Strategy in Parkinson’s disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model

et al. 2020

View full text Add to dashboard Cite

Patients with Parkinson’s disease (PD) manifest nonmotor and motor symptoms. Autonomic cardiovascular dysregulation is a common nonmotor manifestation associated with increased morbimortality. Conventional clinical treatment alleviates motor signs but does not change disease progression and fails in handling nonmotor features. Nutrition is a key modifiable determinant of chronic disease. This study aimed to assess the effects of propolis on cardiological features, heart rate (HR) and heart rate variability (HRV) and on nigrostriatal dopaminergic damage, detected by tyrosine hydroxylase (TH) immunoreactivity, in the 6-hydroxydopamine (6-OHDA) rat model of PD. Male Wistar rats were injected bilaterally with 6-OHDA or saline into the striatum and were treated with propolis or water for 40 days. Autonomic function was assessed by time domain parameters (standard deviation of all normal-to-normal intervals (SDNN) and square root of the mean of the squared differences between adjacent normal RR intervals (RMSSD)) of HRV calculated from electrocardiogram recordings. Reductions in HR (p = 1.47 × 10−19), SDNN (p = 3.42 × 10−10) and RMSSD (p = 8.2 × 10−6) detected in parkinsonian rats were reverted by propolis. Propolis attenuated neuronal loss in the substantia nigra (p = 5.66 × 10−15) and reduced striatal fiber degeneration (p = 7.4 × 10−5) in 6-OHDA-injured rats, which also showed significant weight gain (p = 1.07 × 10−5) in comparison to 6-OHDA-lesioned counterparts. Propolis confers cardioprotection and neuroprotection in the 6-OHDA rat model of PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Propolis as a Potential Disease-Modifying Strategy in Parkinson’s disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To date, few studies have evaluated NO in the cardiovascular system of animals with parkinsonism de Jager et al (2018) observed differences in tissue concentrations of nitrite in sedentary animals or animals submitted to physical training before 6-OHDA injury, with NO being increased in the aorta of 6-OHDA animals compared to their controls. However, inhibition of NOS by L-NAME administration promoted a smaller increase in MAP in 6-OHDA animals, suggesting that eNOS nitrergic tonus is lower in animals injured by 6-OHDA than in Sham animals ( de Jager et al, 2018 ). In this sense, it is possible that different isoforms are participating in these responses.…”

Section: Nitric Oxide In Cardiovascular Dysfunction In Parkinson's Di...mentioning

confidence: 99%

Nitric Oxide Involvement in Cardiovascular Dysfunctions of Parkinson Disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra, causing motor changes. In addition to motor symptoms, non-motor dysfunctions such as psychological, sensory and autonomic disorders are recorded. Manifestations related to the autonomic nervous system include the cardiovascular system, as postural hypotension, postprandial hypotension, and low blood pressure. One of the mediators involved is the nitric oxide (NO). In addition to the known roles such as vasodilator, neuromodulator, NO acts as an important mediator of the immune response, increasing the inflammatory response provoked by PD in central nervous system. The use of non-specific NOS inhibitors attenuated the neurodegenerative response in animal models of PD. However, the mechanisms by which NO contributes to neurodegeneration are still not well understood. The literature suggest that the contribution of NO occurs through its interaction with superoxides, products of oxidative stress, and blocking of the mitochondrial respiratory chain, resulting in neuronal death. Most studies involving Parkinsonism models have evaluated brain NO concentrations, with little data available on its peripheral action. Considering that studies that evaluated the involvement of NO in the neurodegeneration in PD, through NOS inhibitors administration, showed neuroprotection in rats, it has prompted new studies to assess the participation of NOS isoforms in cardiovascular changes induced by parkinsonism, and thus to envision new targets for the treatment of cardiovascular disorders in PD. The aim of this study was to conduct a literature review to assess available information on the involvement of nitric oxide (NO) in cardiovascular aspects of PD.

show abstract

“…Interestingly, ovarian hormones seem to have a cardiac protective role against intracranial 6-OHDA intoxication in rats [151]. Males bilaterally infused in the SNpc with 6-OHDA showed a decreased mean arterial pressure and heart rate, and increased nitric oxide (NO) levels in the heart and aorta compared to sham animals [69,152]. On the contrary, females did not show changes in those parameters, but when they were subjected to ovariectomy, arterial pressure values, heart rate and NO levels were similar to the males [151].…”

Section: Experimental Models Of Parkinsonismmentioning

confidence: 99%

Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence

Cuenca‐Bermejo

Almela

Navarro‐Zaragoza

et al. 2021

IJMS

View full text Add to dashboard Cite

Dysautonomia is a common non-motor symptom in Parkinson’s disease (PD). Most dysautonomic symptoms appear due to alterations in the peripheral nerves of the autonomic nervous system, including both the sympathetic and parasympathetic nervous systems. The degeneration of sympathetic nerve fibers and neurons leads to cardiovascular dysfunction, which is highly prevalent in PD patients. Cardiac alterations such as orthostatic hypotension, heart rate variability, modifications in cardiogram parameters and baroreflex dysfunction can appear in both the early and late stages of PD, worsening as the disease progresses. In PD patients it is generally found that parasympathetic activity is decreased, while sympathetic activity is increased. This situation gives rise to an imbalance of both tonicities which might, in turn, promote a higher risk of cardiac damage through tachycardia and vasoconstriction. Cardiovascular abnormalities can also appear as a side effect of PD treatment: L-DOPA can decrease blood pressure and aggravate orthostatic hypotension as a result of a negative inotropic effect on the heart. This unwanted side effect limits the therapeutic use of L-DOPA in geriatric patients with PD and can contribute to the number of hospital admissions. Therefore, it is essential to define the cardiac features related to PD for the monitorization of the heart condition in parkinsonian individuals. This information can allow the application of intervention strategies to improve the course of the disease and the proposition of new alternatives for its treatment to eliminate or reverse the motor and non-motor symptoms, especially in geriatric patients.

show abstract

Nitric oxide alterations in cardiovascular system of rats with Parkinsonism induced by 6-OHDA and submitted to previous exercise

Cited by 9 publications

References 50 publications

Propolis as a Potential Disease-Modifying Strategy in Parkinson’s disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model

Propolis as a Potential Disease-Modifying Strategy in Parkinson’s disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model

Nitric Oxide Involvement in Cardiovascular Dysfunctions of Parkinson Disease

Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence

Contact Info

Product

Resources

About